These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 26407728)

  • 21. Differential pricing of new pharmaceuticals in lower income European countries.
    Kaló Z; Annemans L; Garrison LP
    Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology.
    Inotai A; Pékli M; Jóna G; Nagy O; Remák E; Kaló Z
    BMC Health Serv Res; 2012 Sep; 12():332. PubMed ID: 22999574
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
    Thatte U; Hussain S; de Rosas-Valera M; Malik MA
    Value Health; 2009; 12 Suppl 3():S18-25. PubMed ID: 20586975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health technology assessment. The pharmaceutical industry perspective.
    Schubert F
    Int J Technol Assess Health Care; 2002; 18(2):184-91. PubMed ID: 12053418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
    Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
    Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
    Akehurst RL; Abadie E; Renaudin N; Sarkozy F
    Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
    Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
    Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
    Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
    Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
    Enzing JJ; Himmler S; Knies S; Brouwer WBF
    Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.